Literature DB >> 30132020

Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway.

Xiuli Fang1, Yajun Liu1, Jing Lu1, Huiqi Hong1, Jing Yuan1, Yuhong Zhang1, Panxia Wang1, Peiqing Liu1, Jiantao Ye2.   

Abstract

Protocatechuic aldehyde (PCA) is a natural compound found in the Chinese herb Salvia miltiorrhiza. It has been shown to possess multiple biological activities and to protect the cardiovascular system against oxidative stress, inflammation, and atherosclerosis. However, the potential effects of PCA on cardiac hypertrophy remain to be investigated. In this study, we showed that isoproterenol treatment (ISO, 10 μM for 24 h) induced significant hypertrophy in cultured neonatal rat cardiomyocytes, as manifested by enlargement of cell surface area (1.74-fold greater than that of the control, p < 0.05) and upregulation of hypertrophic gene markers (2.44- to 2.75-fold increase in ANF and β-MHC protein expression, p < 0.05). These ISO-induced hypertrophic responses were attenuated by PCA (50-200 μM, p < 0.05). Furthermore, intragastric administration of PCA (10-100 mg/kg/day) ameliorated cardiac hypertrophy in ISO-treated rats (1.5 mg/kg/day, s.c., for 7 days). PCA inhibited the abnormal changes in echocardiographic parameters and suppressed ISO-induced increase in cardiomyocyte cross-sectional area and collagen content (p < 0.05). It also ameliorated ISO-mediated elevation of HW/BW, LVW/BW, and HW/TL ratios (p < 0.05). Mechanistically, ISO facilitated JAK2 and STAT3 phosphorylation, increased STAT3 nuclear translocation, and enhanced STAT3 transcriptional activity. All these changes were attenuated by PCA. Taken together, these findings showed that PCA could protect against cardiac hypertrophy induced by ISO possibly via inhibition of the JAK2/STAT3 signaling pathway, suggesting the potential of PCA as a therapeutic candidate for hypertrophy-associated heart diseases.

Entities:  

Keywords:  Cardiac hypertrophy; Isoproterenol; JAK2/STAT3 pathway; Protocatechuic aldehyde

Mesh:

Substances:

Year:  2018        PMID: 30132020     DOI: 10.1007/s00210-018-1556-7

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  47 in total

1.  The angiotensin II-dependent nuclear translocation of Stat1 is mediated by the Jak2 protein motif 231YRFRR.

Authors:  P P Sayeski; M S Ali; S J Frank; K E Bernstein
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

2.  Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy?

Authors:  Nicole H Purcell; Jeffery D Molkentin
Journal:  Circulation       Date:  2003-08-12       Impact factor: 29.690

3.  Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis.

Authors:  Chang Yoon Moon; Cheol Ryong Ku; Yoon Hee Cho; Eun Jig Lee
Journal:  Biochem Biophys Res Commun       Date:  2012-05-26       Impact factor: 3.575

4.  Protocatechualdehyde Protects Against Cerebral Ischemia-Reperfusion-Induced Oxidative Injury Via Protein Kinase Cε/Nrf2/HO-1 Pathway.

Authors:  Chao Guo; Shiquan Wang; Jialin Duan; Na Jia; Yanrong Zhu; Yi Ding; Yue Guan; Guo Wei; Ying Yin; Miaomaio Xi; Aidong Wen
Journal:  Mol Neurobiol       Date:  2016-01-16       Impact factor: 5.590

5.  Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3 : an autocrine loop for hypertrophy.

Authors:  J Fukuzawa; G W Booz; R A Hunt; N Shimizu; V Karoor; K M Baker; D E Dostal
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

6.  Protocatechuic aldehyde protects against experimental sepsis in vitro and in vivo.

Authors:  Yong Xu; Wang-Lin Jiang; Shu-Ping Zhang; Hai-Bo Zhu; Jian Hou
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-11-24       Impact factor: 4.080

7.  Simultaneous determination of eight Danshen polyphenols in rat plasma and its application to a comparative pharmacokinetic study of DanHong injection and Danshen injection.

Authors:  Xiuxue Li; Feifei Du; Weiwei Jia; Olajide E Olaleye; Fang Xu; Fengqing Wang; Li Li
Journal:  J Sep Sci       Date:  2017-03-07       Impact factor: 3.645

8.  Cardiac oxidative stress in acute and chronic isoproterenol-infused rats.

Authors:  Guo-Xing Zhang; Shoji Kimura; Akira Nishiyama; Takatomi Shokoji; Matlubur Rahman; Li Yao; Yukiko Nagai; Yoshihide Fujisawa; Akira Miyatake; Youichi Abe
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

9.  IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2.

Authors:  Buddhadeb Dawn; Yu-Ting Xuan; Yiru Guo; Arash Rezazadeh; Adam B Stein; Greg Hunt; Wen-Jian Wu; Wei Tan; Roberto Bolli
Journal:  Cardiovasc Res       Date:  2004-10-01       Impact factor: 10.787

Review 10.  Targeting cardiac hypertrophy: toward a causal heart failure therapy.

Authors:  Egbert Bisping; Paulina Wakula; Michael Poteser; Frank R Heinzel
Journal:  J Cardiovasc Pharmacol       Date:  2014-10       Impact factor: 3.105

View more
  3 in total

1.  Recombinant high‑mobility group box 1 induces cardiomyocyte hypertrophy by regulating the 14‑3‑3η, PI3K and nuclear factor of activated T cells signaling pathways.

Authors:  Feifei Su; Miaoqian Shi; Jian Zhang; Yan Li; Jianwei Tian
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

2.  Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1-Sp1-PKCγ axis.

Authors:  Liyan Bai; Hae Jin Kee; Xiongyi Han; Tingwei Zhao; Seung-Jung Kee; Myung Ho Jeong
Journal:  Sci Rep       Date:  2021-08-30       Impact factor: 4.379

3.  Protocatechuic aldehyde from Salvia miltiorrhiza exhibits an anti-inflammatory effect through inhibiting MAPK signalling pathway.

Authors:  Shuang Wu; Qingyu Wang; Jinquan Wang; Baoyu Duan; Qihe Tang; Zhuojian Sun; Jinlong Han; Chenggang Shan; Zhifen Wang; Zhihui Hao
Journal:  BMC Complement Med Ther       Date:  2020-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.